Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James P. Allison"'
Autor:
Sonali Jindal, Paul G. Corn, Fei Duan, Shalini Singh, Sumit K. Subudhi, Curtis A. Pettaway, Christopher J. Logothetis, Bilal A. Siddiqui, Padmanee Sharma, Rebecca S. S. Tidwell, Brian F. Chapin, John M. Ward, James P. Allison
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundProstate cancer is ”immunologically cold,” with enrichment of myeloid populations, immunosuppressive cytokines, and few T cells within the tumor microenvironment (TME). CD38 is expressed on myeloid cells, T cells, plasma B cells, and NK
Autor:
Elie Tannous, Juan Qin, Wouter C. Meijers, Justin M. Balko, Yueli Zhang, Xiaopeng Sun, Margaret L Axelrod, Douglas B. Johnson, Susan R. Opalenik, Elizabeth Wescott, James P. Allison, Spencer C. Wei, Elles M. Screever, Javid Moslehi, Ayaka Sugiura
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundNearly half of all U.S. oncology patients meet FDA eligibility criteria to receive treatment with an immune checkpoint inhibitor (ICI). With increasing use of ICIs, preventing, diagnosing and treating immune-related adverse events (irAEs) a
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Autor:
Matthew J. Reilley, Vivek Subbiah, Aung Naing, Daniel D. Karp, Funda Meric-Bernstam, Jo Ann Lim, David S. Hong, Filip Janku, Stacie Bean, Siqing Fu, Allison Bass, Sarina Anne Piha-Paul, Sandra Montez, Luis M Vence, Apostolia Maria Tsimberidou, Ann Marie Bailey, Gerald Steven Falchook, James P. Allison, Padmanee Sharma
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-10 (2017)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumu